Evidence map›Paper›PMID 38340268›Full record

ArticleCell biology and toxicology2024

Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma.

Jian-Wen Di, Yi-Xin Wang, Rui-Xue Ma, Zhi-Jie Luo, Wen-Ting Chen, Wan-Mei Liu, Ding-Yi Yuan, Yu-Ying Zhang, Yin-Hao Wu, Cai-Ping Chen and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biology and toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jian-Wen DiNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Yi-Xin WangNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Rui-Xue MaNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Zhi-Jie LuoNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Wen-Ting ChenNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Wan-Mei LiuNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Ding-Yi YuanNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Yu-Ying ZhangNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Yin-Hao WuNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
Cai-Ping ChenState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. caiping.chen@cpu.edu.cn.
Jun LiuNew Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China. junliu@cpu.edu.cn.
National Center for Drug Screening · CNChina Pharmaceutical University · CNChongqing University · CN

Funding

National Natural Science Foundation of China 81973361Natural Science Foundation of Jiangsu Province BK20202009Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission CSTB2022NSCQ-MSX1649
6 · The paper itself

Abstract

V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA), a novel negative checkpoint regulator, plays an essential role in allergic pulmonary inflammation in mice. Treatment with a VISTA agonistic antibody could significantly improve asthma symptoms. Thus, for allergic asthma treatment, VISTA targeting may be a compelling approach. In this study, we examined the functional mechanism of VISTA in allergic pulmonary inflammation and screened the FDA-approved drugs for VISTA agonists. By using mass cytometry (CyTOF), we found that VISTA deficiency primarily increased lung macrophage infiltration in the OVA-induced asthma model, accompanied by an increased proportion of M1 macrophages (CD11b

Indexed as

AsthmaDibenzothiepinsPneumoniaPyridonesTriazinesAnimalsMembrane ProteinsMiceMorpholinesbaloxavirDibenzothiepinsMembrane ProteinsMorpholinesPyridonesTriazinesVsir protein, mouseAsthmaBaloxavir marboxilMacrophage polarizationVISTA

Identifiers

PMID38340268
PMCPMC10858940
OpenAlexW4391719709

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.